Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: Correlation with intravesical recurrence following transurethral resection

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 5, 2011, Pages 495-501

  Behnsawy, Hosny M ^a,b   Miyake, Hideaki ^a   Abdalla, Medhat A ^b   Sayed, Mohamed A ^b   Ahmed, Abd El Fattah I ^b   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Assiut University Faculty of Medicine   (Egypt)

Author keywords

Cell cycle associated protein; Intravesical recurrence; Non muscle invasive bladder cancer; Transurethral resection

Indexed keywords

AURORA A KINASE; CELL CYCLE PROTEIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CARCINOMA IN SITU; CYSTECTOMY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; RISK ASSESSMENT; SURVIVAL TIME; TRANSURETHRAL BLADDER RESECTION;

CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE PROTEINS; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MUSCLE NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 80052920906     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.08.002     Document Type: Article

References (30)

1. Oosterlinck W. The management of superficial bladder cancer. BJU Int 2001, 87:135-140.
2. Hisataki T., Miyao N., Masumori N., et al. Risk factors for multiple intravesical recurrences of superficial bladder cancer. Urology 2001, 58:935-939.
3. Millan-Rodriguez F., Chechile-Toniolo G., Salvador-Bayarri J., et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000, 163:73-78.
4. Millan-Rodriguez F., Chechile-Toniolo G., Salvador-Bayarri J., et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000, 164:680-684.
5. Ali-El-Dein B., Sarhan O., Hinev A., et al. Superficial bladder tumours: Analysis of prognostic factors and construction of a predictive index. BJU Int 2003, 92:393-399.
6. Kaasinen E., Rintala E., Hellstrom P., et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 2002, 42:167-174.
7. Sakai I., Miyake H., Harada K., et al. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ. Int J Urol 2006, 13:1389-1392.
8. Sgambato A., Migaldi M., Faraglia B., et al. Cyclin D1 expression in papillary superficial bladder cancer: Its association with other cell cycle-associated proteins, cell proliferation and clinical outcome. Int J Cancer 2002, 97:671-678.
9. Mhawech-Fauceglia P., Fischer G., Alvarez V., et al. Predicting outcome in minimally invasive (T1a and T1b) urothelial bladder carcinoma using a panel of biomarkers: A high throughput tissue microarray analysis. BJU Int 2007, 100:1182-1187.
10. Burger M., Denzinger S., Hartmann A., et al. Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67, and histological grade. Br J Cancer 2007, 96:1711-1715.
11. Lopez-Beltran A., Luque R.J., Alvarez-Kindelan J., et al. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: The role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am J Clin Pathol 2004, 122:444-452.
12. Mhawech-Fauceglia P., Fischer G., Beck A., et al. Raf1, Aurora-A/STK15, and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma: A retrospective TMA study of 246 patients with long-term follow-up Eur. J Surg Oncol 2006, 32:439-444.
13. Choi Y.D., Cho N.H., Ahn H.S., et al. Matrix metalloproteinase expression in the recurrence of superficial low grade bladder transitional cell carcinoma. J Urol 2007, 177:1174-1178.
14. Miyake H., Gleave M., Kamidono S., et al. Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology 2002, 59:150-154.
15. Theodoropoulos V.E., Lazaris A.C., Kastriotis I., et al. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumor recurrence and progression in superficial urothelial bladder carcinoma. BJU Int 2005, 95:425-431.
16. Santos L., Amaro T., Costa C., et al. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification. Int J Cancer 2003, 105:267-272.
17. Pfister C., Moore L., Allard P., et al. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 1999, 5:4079-4084.
18. Chow N.H., Tzai T.S., Cheng H.L., et al. The clinical value of p21WAF1/CIP1 expression in superficial bladder cancer. Anticancer Res 2000, 20:1173-1176.
19. Garcia-España A., Salazar E., Sun T.T., et al. Differential expression of cell cycle regulators in phenotypic variants of transgenically induced bladder tumors: Implications for tumor behavior. Cancer Res 2005, 65:1150-1157.
20. May F., Treiber U., Hartung R., et al. Significance of random bladder biopsies in superficial bladder cancer. Eur Urol 2003, 44:47-50.
21. Kurahashi T., Miyake H., Hara I., et al. Expression of major heat shock proteins in prostate cancer: Correlation with clinicopathologic outcomes in patients undergoing radical prostatectomy. J Urol 2007, 177:757-761.
22. Inoue T., Segawa T., Shiraishi T., et al. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 2005, 66:332-337.
23. Zellweger T., Ninck C., Bloch M., et al. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005, 113:619-628.
24. Williams S.G., Stein J.P. Molecular pathways in bladder cancer. Urol Res 2004, 32:373-385.
25. Gartel A.L., Radhakrishnan S.K. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005, 65:3980-3985.
26. Kurahashi T., Miyake H., Hara I., et al. Significance of Aurora-A expression in renal cell carcinoma. Urol Oncol 2007, 25:128-133.
27. Migaldi M., Sgambato A., Garagnani L., et al. Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers. Clin Cancer Res 2000, 6:3131-3138.
28. Liukkonen T., Lipponen P., Raitanen M., et al. Evaluation of p21WAF1/CIP1 and cyclin D1 expression in the progression of superficial bladder cancer. Finn Bladder Group. Urol Res 2000, 28:285-292.
29. Shariat S.F., Ashfaq R., Sagalowsky A.I., et al. Predictive value of cell cycle biomarkers in non-muscle-invasive bladder transitional cell carcinoma. J Urol 2007, 177:481-487.
30. Santos L.L., Amaro T., Pereira S.A., et al. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder. Eur J Surg Oncol 2003, 29:74-80.